Cynata Therapeutics Limited

DB:51S Stock Report

Market Cap: €36.1m

Cynata Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:51S Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
23 Jan 25Buy€6,031Geoffrey Edward BrookeIndividual55,555€0.11
23 Jan 25Buy€21,710Paul WottonIndividual200,000€0.11
23 Jan 25Buy€15,076Janine RolfeIndividual138,888€0.11
23 Jan 25Buy€19,298Kilian KellyIndividual177,777€0.11
23 Jan 25Buy€7,237Darryl MaherIndividual66,666€0.11

Insider Trading Volume

Insider Buying: 51S insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 51S?
Owner TypeNumber of SharesOwnership Percentage
Private Companies00%
Public Companies8,088,4033.59%
Institutions9,506,6254.22%
Individual Insiders18,583,9028.25%
VC/PE Firms23,588,04010.5%
General Public165,478,74673.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.4%.

Top Shareholders

Top 19 shareholders own 26.53% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.5%
Bioscience Managers Pty Ltd
23,588,040€3.8m0%69.29%
4.22%
Fidelity International Ltd
9,506,625€1.5m0%no data
3.59%
FUJIFILM Holdings Corporation
8,088,403€1.3m0%no data
1.58%
Kenneth Wilson
3,549,905€569.3k0%no data
1.05%
Aily Lamb
2,360,000€378.4k0%no data
0.89%
Ross MacDonald
2,000,000€320.7k0%no data
0.77%
Craig Darby
1,729,477€277.3k55.8%no data
0.69%
Malcolm Washer
1,559,534€250.1k0%no data
0.6%
Patrick Walsh
1,341,790€215.2k0%no data
0.53%
Makysm Vodyanyk
1,191,658€191.1k0%no data
0.35%
Kilian Kelly
797,428€127.9k28.7%no data
0.34%
Miroslawa Rej
771,518€123.7k0%no data
0.34%
Pawel Rej
771,518€123.7k0%no data
0.29%
Jon Bjarnason
655,517€105.1k9.25%no data
0.29%
Rina Bjarnason
655,517€105.1k9.25%no data
0.23%
Paul Wotton
515,309€82.6k63.4%no data
0.14%
Geoffrey Edward Brooke
312,898€50.2k21.6%no data
0.11%
Janine Rolfe
255,167€40.9k119%no data
0.052%
Darryl Maher
116,666€18.7k133%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 19:47
End of Day Share Price 2025/02/06 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cynata Therapeutics Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Chris KallosMST Financial Services Pty Limited
Raghuram SelvarajuRodman & Renshaw, LLC